Ehab Atallah - Concepedia

Author

Ehab Atallah

Also Known As

E Atallah, E. Atallah, E. L. Atallah, E.L. Atallah, Ehab Atallah, Ehab L Atallah, Ehab L. Atallah, Eliane Atallah, Steven Rosen

359

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Medical College of Wisconsin Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Mayo Clinic in Arizona Fred Hutch Cancer Center

About

Ehab Atallah is an author at Medical College of Wisconsin specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	840
2	Health Sciences	9	9	490
3	Cell Biology	3	3	132
4	Blood Transplantation	2	2	48
5	Public Health	1	1	39

Ehab Atallah

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Congestive heart failure is a rare event in patients receiving imatinib therapy Ehab Atallah, Jean‐Bernard Durand, Hagop Kantarjian, Blood	2007	252
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117 Mikkael A. Sekeres, Megan Othus, Alan F. List, Journal of Clinical Oncology	2017	236
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, New England Journal of Medicine	2024	171
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial Guillermo Garcia‐Manero, Pierre Fenaux, Aref Al‐Kali, The Lancet Oncology Family MedicineBone Marrow FailureHematologyClinical TrialsPharmacotherapy	2016	168
Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Blood	2022	132
Imatinib and <i>Panax Ginseng</i>: A Potential Interaction Resulting in Liver Toxicity Naveen Bilgi, Ashwin N. Ananthakrishnan, Ehab Atallah Annals of Pharmacotherapy	2010	116
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial Nitin Jain, Emily Curran, Neil M. Iyengar, Clinical Cancer Research	2013	111
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS) Wael Saber, Corey Cutler, Ryotaro Nakamura, Blood	2013	101
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia Ehab Atallah, Charles A. Schiffer, Jerald P. Radich, JAMA Oncology	2020	101
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia Ehab Atallah, Jörge E. Cortes, Susan O’Brien, Blood	2007	92

Page 1